CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 106 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q3 2019. The put-call ratio across all filers is 1.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $88,000 | +57.1% | 44,766 | +0.3% | 0.00% | – |
| Q4 2020 | $56,000 | -30.0% | 44,648 | -0.0% | 0.00% | – |
| Q3 2020 | $80,000 | -76.5% | 44,659 | +10.2% | 0.00% | -100.0% |
| Q2 2020 | $340,000 | +66.7% | 40,520 | +4.0% | 0.00% | +100.0% |
| Q1 2020 | $204,000 | +0.5% | 38,974 | +4.9% | 0.00% | 0.0% |
| Q4 2019 | $203,000 | +10.9% | 37,171 | -0.8% | 0.00% | 0.0% |
| Q3 2019 | $183,000 | -30.2% | 37,482 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $262,000 | +8.3% | 37,744 | +8.2% | 0.00% | 0.0% |
| Q1 2019 | $242,000 | +26.0% | 34,869 | +6.2% | 0.00% | 0.0% |
| Q4 2018 | $192,000 | -23.2% | 32,841 | -0.8% | 0.00% | 0.0% |
| Q3 2018 | $250,000 | +52.4% | 33,093 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $164,000 | -14.6% | 32,497 | +3.5% | 0.00% | 0.0% |
| Q1 2018 | $192,000 | -17.2% | 31,396 | -3.8% | 0.00% | 0.0% |
| Q4 2017 | $232,000 | +9.4% | 32,650 | +10.0% | 0.00% | 0.0% |
| Q3 2017 | $212,000 | +22.5% | 29,694 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $173,000 | – | 27,474 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $3,107,000 | 1.71% |
| ETF MANAGERS GROUP, LLC | 14,138,998 | $8,534,000 | 0.17% |
| Ikarian Capital, LLC | 948,526 | $584,000 | 0.09% |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 318,668 | $196,000 | 0.03% |
| Platform Technology Partners | 45,000 | $28,000 | 0.01% |
| XTX Topco Ltd | 34,476 | $21,000 | 0.01% |
| PINNACLE ASSOCIATES LTD | 947,083 | $583,000 | 0.01% |
| Penserra Capital Management LLC | 537,236 | $330,000 | 0.01% |
| Mirae Asset Global Investments Co., Ltd. | 4,070,006 | $2,506,000 | 0.01% |
| Tekla Capital Management LLC | 154,310 | $95,000 | 0.00% |